FinTrust Capital Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History

FinTrust Capital Advisors’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$2.34K	Hold	21	–	–	﹤0.01%	1194
2024 Q2	$2.24K	Sell	21 -2	-9%	-$220	﹤0.01%	1182
2024 Q1	$2.77K	Hold	23	–	–	﹤0.01%	1073
2023 Q4	$2.83K	Hold	23	–	–	﹤0.01%	1045
2023 Q3	$2.98K	Hold	23	–	–	﹤0.01%	964
2023 Q2	$3.67K	Hold	23	–	–	﹤0.01%	927
2023 Q1	$3.67K	Hold	23	–	–	﹤0.01%	920
2022 Q4	$3.66K	Buy	23 +16	+229%	+$2.35K	﹤0.01%	918
2022 Q3	$1K	Hold	7	–	–	﹤0.01%	1170
2022 Q2	$1K	Hold	7	–	–	﹤0.01%	1171
2022 Q1	$1K	Sell	7 -78	-92%	-$11.3K	﹤0.01%	1175
2021 Q4	$11K	Sell	85 -44	-34%	-$5.78K	﹤0.01%	900
2021 Q3	$17K	Sell	129 -5	-4%	-$755	﹤0.01%	776
2021 Q2	$24K	Buy	134 +12	+10%	+$2.08K	0.01%	713
2021 Q1	$20K	Sell	122 -36	-23%	-$5.92K	0.01%	717
2020 Q4	$26K	Buy	+158	New	+$23.5K	0.01%	615

Other funds holding JAZZ

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

FinTrust Capital Advisors's JAZZ Position: Q3 2024 in Review

FinTrust Capital Advisors held its Jazz Pharmaceuticals (JAZZ) position steady in Q3 2024 at 21 shares worth $2.34K. The position accounts for ﹤0.01% of the portfolio, ranked #1194.

FinTrust Capital Advisors first reported a position in JAZZ in Q4 2020 and has held it in 16 quarters since. The position peaked at $26K in Q4 2020. 477 funds tracked by Wall St. Rank hold JAZZ as of Q3 2024.

FinTrust Capital Advisors held 21 shares of Jazz Pharmaceuticals worth $2.34K as of Q3 2024.
FinTrust Capital Advisors left its Jazz Pharmaceuticals share count unchanged in Q3 2024.
Jazz Pharmaceuticals made up ﹤0.01% of FinTrust Capital Advisors's portfolio in Q3 2024, its #1194 holding.
FinTrust Capital Advisors first reported a position in Jazz Pharmaceuticals in Q4 2020 and has held it in 16 quarters since.
FinTrust Capital Advisors's Jazz Pharmaceuticals position peaked at $26K in Q4 2020.
477 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2024.

Based on FinTrust Capital Advisors's 13F filing for Q3 2024, filed 11 Oct 2024.